ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The FDA sends the maker of enclomiphene back to drawing board
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 28325" data-attributes="member: 3"><p><strong>Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene</strong></p><p></p><p></p><p>THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. A Complete Response Letter is a communication from theFDA that informs companies that an application cannot be approved in its present form.</p><p></p><p></p><p>In the letter, the FDA stated that, based on recent scientific developments,<strong> the design of enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that </strong><strong>Repros</strong><strong> conduct an additional Phase 3 study or studies to support approval in the target population. The </strong><strong>FDA</strong><strong> also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.</strong></p><p></p><p></p><p></p><p>Repros plans to work with the FDA to determine an appropriate path forward to address these comments. "We are disappointed that the FDA has taken this position without the benefit of an advisory committee recommendation," said </p><p>Joseph Podolski, President and CEO of Repros. "We plan to work closely with the Agency to gain more information to determine the appropriate next steps regarding the enclomiphene application."</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 28325, member: 3"] [B]Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene[/B] THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. A Complete Response Letter is a communication from theFDA that informs companies that an application cannot be approved in its present form. In the letter, the FDA stated that, based on recent scientific developments,[B] the design of enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that [/B][B]Repros[/B][B] conduct an additional Phase 3 study or studies to support approval in the target population. The [/B][B]FDA[/B][B] also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.[/B] Repros plans to work with the FDA to determine an appropriate path forward to address these comments. "We are disappointed that the FDA has taken this position without the benefit of an advisory committee recommendation," said Joseph Podolski, President and CEO of Repros. "We plan to work closely with the Agency to gain more information to determine the appropriate next steps regarding the enclomiphene application." [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The FDA sends the maker of enclomiphene back to drawing board
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top